Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. (Q46106006)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 September 2012

Language	Label	Description	Also known as
English	Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.	scientific article published on 28 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

0 references

1 reference

based on heuristic

inferred from title

Robert L. Murphy

11

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Sidonie Lambert-Niclot

5

object named as

Sidonie Lambert-Niclot

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Christine Katlama

14

object named as

Christine Katlama

0 references

Philippe Flandre

object named as

Philippe Flandre

12

0 references

Gilles Peytavin

13

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

9

object named as

Anne Simon

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Claudine Duvivier

8

object named as

Claudine Duvivier

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Luminita Schneider

6

object named as

Luminita Schneider

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

2

object named as

Laurence Slama

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

1

object named as

Jade Ghosn

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Allal Houssaini

4

object named as

Allal Houssaini

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

author name string

Aziza Chermak

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Erwan Fourn

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Eve Courbon

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

RADAR Study Group

15

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

publication date

28 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

85

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

8-15

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Better adherence with once-daily antiretroviral regimens: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Men who have sex with men have a 140-fold higher risk for newly diagnosed HIV and syphilis compared with heterosexual men in New York City

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Orofacial effects of antiretroviral therapies

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23404

21 January 2018

Identifiers

10.1002/JMV.23404

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/23024008

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46106006&oldid=2101031882"